Xi'an Prius Biological Engineering Co.,Ltd
Address:Room 0836,Euro-Asia International Building A,Ouya avenue ,Xi'an,Shaanxi Province ,China.
The longspur epimedium is a kind of whole plant that can be used for medicine, the main treatment in Chinese medicine is impotence premature ejaculation, aching feet, numbness of limbs, half-body failure, nervous weakness, forgetfulness, tinnitus, dizziness and other disorders.
On May 19, 2021, at the annual meeting of the American Society of Clinical Oncology (ASCO), China self-developed the small molecule immunogenic innovation drug, Epimedium extract is efficacious in the therapy of advanced hepatocellular carcinoma, the research results were released for the first time.
In June, Cancer Science, an international journal of cancer, published online the results of a phase II clinical trial of the natural small molecule Acoradine First-in-class immunomodulation for advanced hepatocellular carcinoma.
Acorardin (SNG-162, common name for Icariin) is an active drug monomer extracted, isolated and purified from longspur epimedium, which is developed as a new type of Chinese medicine for the treatment of advanced liver cancer , it is considered to be another major breakthrough in the modernization of Chinese medicine after artemisinin.
The study included 283 patients with advanced hepatocellular carcinoma since September 2017, 71 of whom had positive comprehensive biomarkers, accompanied by dangerous or adverse prognosis factors such as late stage (BCLC C), HBV infection and platelet reduction, of whom 33 received treatment for epimedium extract and 38 received treatment for valium.
The medium follow-up time is 8.1 months (deadline: December 30, 2020), effective research data as of November 2, 2020 show:
In the compound biomarker-rich population, it was found that the medium survival (mOS) of the Acorardin treatment group was better than that of the control group of valium, which was 13.5 months to 6.8 months, indicating that Acorardin was indeed able to reduce the risk of death in patients with advanced liver cancer, reaching 57%, with significant survival advantages, it is very valuable.
On the other hand, the advantages of epimedium extract are also reflected in the safety data good, drug-related adverse reactions of level 3 and above incidence of only 15%, which is consistent with the past phase I, II clinical trial safety data, that is, it has good safety.
The small molecule immunomodulator epimedium extract can significantly improve the overall survival rate of patients with advanced liver cancer presenting a positive rich hepatitis B virus (HBV) correlation with poor comprehensive biomarker scores, which is safe.
At present, the drug has submitted to the State Drug Administration listing application, it has been received, and included in the priority approval.
If you want know more, please contact: [email protected]